Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Hopeforthebeston Sep 11, 2023 12:00pm
94 Views
Post# 35629489

Reaction to new "News Release"

Reaction to new "News Release"Anyone see the just released report from gagnon.

CZO is getting well ahead of the game and planning for clinic trials of their avenanthramides at the Montreal Heart institue. CZO avenanthramides have proven to be effect in containing heart swelling due to the COVID Virus. 

In order to prepare for the clinic trials and subsquent human trials, gagnon is working closely with his production group and scientist to ensure that sufficient quantity and quality of the avenanthramides if available. gagnon is quoted to saying "Considering the timeline it will be difficult to achieve but we are hopeful". The trial date is slated to occur during the next pandemics which historically will be 100 years form now, give or take 10 years.
gagnon also mentioned that GILLE GAGNON 3rd will be CEO and will heading the trial.

Ronnie Miller was to add further comments but failed to show up for the Press Release.
<< Previous
Bullboard Posts
Next >>